Journal of Urgent Care Medicine

Retailers Shift To GLP-1 Programs—What It Means For Urgent Care

Big retailers are still attempting to shape new clinical lines of business, betting that some of them will eventually become profitable. Attention has now turned to GLP-1s. Yet against this backdrop, healthcare’s market reality is still leading to scaled-back expansion plans, noticeable exits, and massive financial write-downs for some retailers. The market is rather hit-or-miss right now. For example, Amazon continues to open primary care clinics through health system partnerships (including about 200 sites, according …

GLP-1 Users May Have Higher Risk For Chronic Cough

Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) may be associated with chronic cough, as published in JAMA Otolaryngology–Head & Neck Surgery. A large study of more than 2 million people with type 2 diabetes across 70 healthcare organizations suggests that adults prescribed a GLP-1RA had a 12% higher risk for developing a new cough persisting for more than 8 weeks, compared with people prescribed other medications, including dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) …

GLP-1 Scripts As High As 34% For Those With Diabetes And Obesity

From 2010 to 2024, prescriptions for glucagon-like peptide 1 receptor agonists (GLP-1RAs) increased substantially among individuals with type 2 diabetes (T2D) and obesity, according to a research letter in JAMA Network Open, which examined electronic medical records of more than 300 million Americans. Rates rose from 2.4% to 34.3% among individuals with both T2D and obesity; from 0.6% to 13.7% in those with T2D only; and 0.04% to 7.1% in those with obesity only. The …

Login to JUCM